Wegovy Insurance New Hampshire — Coverage Guide 2026

Wegovy Insurance New Hampshire — Coverage Guide 2026

New Hampshire's insurance landscape for Wegovy (semaglutide 2.4mg) operates under a strict prior authorization framework that most patients encounter only after their first pharmacy rejection. Anthem Blue Cross Blue Shield of New Hampshire, Harvard Pilgrim, and Cigna. The three largest commercial carriers in the state. All classify Wegovy as a specialty medication requiring step therapy documentation, BMI verification, and in some cases, proof of previous weight loss program participation. The rejection rate for initial Wegovy prior authorization requests in New Hampshire exceeded 40% in 2025, according to data compiled by the New Hampshire Insurance Department. That's not because the medication doesn't work. It's because formulary committees demand documentation most primary care offices don't generate during routine visits.

Our team has worked with hundreds of New Hampshire patients navigating this exact process. The gap between eligibility and approval comes down to three documentation elements most providers miss: continuous BMI tracking over at least three months, documented failure of at least one previous weight loss intervention, and explicit notation of weight-related comorbidities using ICD-10 codes that trigger formulary approval pathways.

What is Wegovy insurance coverage in New Hampshire?

Wegovy insurance coverage in New Hampshire refers to the extent to which commercial health plans, Medicare Advantage, and Medicaid (NH Medicaid Standard, NH Medicaid Expansion) reimburse the monthly cost of Wegovy prescriptions. Typically $1,349–$1,570 per month without coverage. Most plans classify Wegovy as a Tier 4 or Tier 5 specialty drug requiring prior authorization, step therapy, and ongoing BMI documentation to maintain approval. Approval rates vary significantly by carrier, with commercial plans approving 55–70% of medically justified requests and Medicare Advantage plans approving fewer than 30% due to Medicare Part D's statutory exclusion of weight loss medications.

New Hampshire Insurance Carriers and Wegovy Formulary Placement

Wegovy's formulary tier placement determines your out-of-pocket cost before you ever submit a prior authorization request. Anthem BCBS of New Hampshire places Wegovy on Tier 4 for most commercial plans, requiring 30% coinsurance after deductible. That translates to $400–$470 per monthly injection if your deductible is met. Harvard Pilgrim's 2026 formulary moved Wegovy to Tier 5 (non-preferred specialty) for employer-sponsored plans, increasing coinsurance to 40–50% and adding mandatory step therapy requiring documented trial of at least one other anti-obesity medication like phentermine or orlistat before Wegovy approval.

Cigna's New Hampshire formulary still classifies Wegovy as Tier 4 but enforces the strictest prior authorization criteria of the three major carriers. Requiring not just BMI ≥30 (or ≥27 with comorbidity) but also documented participation in a structured weight management program within the past six months. Matthew Thornton Health Plan and Ambetter from NH Healthy Families both exclude Wegovy entirely from their individual marketplace formularies as of January 2026, meaning zero coverage regardless of medical necessity.

The practical implication: before starting Wegovy, call your insurer's pharmacy benefits line and ask two specific questions. 'What tier is Wegovy on my specific plan?' and 'What prior authorization criteria must my provider document?' Generic answers about 'weight loss medication coverage' are insufficient. You need the specific PA form your insurer uses and the exact documentation requirements.

Prior Authorization Requirements for Wegovy in New Hampshire

Prior authorization for Wegovy insurance in New Hampshire follows a three-tier documentation structure that most denials trace back to. Tier 1 is baseline eligibility: BMI ≥30 kg/m² documented within the past 90 days, or BMI ≥27 kg/m² with at least one weight-related comorbidity (type 2 diabetes, hypertension, obstructive sleep apnea, dyslipidemia, or cardiovascular disease). The comorbidity must be coded using the specific ICD-10 codes insurers recognize. E11.9 for type 2 diabetes, I10 for hypertension, G47.33 for obstructive sleep apnea. Writing 'patient has high blood pressure' in clinical notes doesn't trigger formulary approval pathways the way proper ICD-10 coding does.

Tier 2 is step therapy documentation. Proof that the patient attempted and failed (or could not tolerate) at least one previous weight loss intervention. Most New Hampshire carriers accept documented trial of phentermine, orlistat, naltrexone-bupropion, or a supervised behavioral weight loss program lasting at least 12 weeks. The failure must be documented with specific language: 'Patient trialed phentermine 37.5mg daily for 16 weeks with <5% body weight reduction' is acceptable. 'Patient says diet and exercise didn't work' is not.

Tier 3 is the justification narrative. A prescriber letter explaining why Wegovy specifically is medically necessary for this patient. Template letters almost always fail. Effective justification letters cite the patient's specific BMI trajectory, the presence of comorbidities that increase cardiovascular risk, and reference clinical trial data (STEP trials) showing Wegovy's superiority to previous interventions the patient tried. Insurance medical directors reviewing PA requests are looking for evidence the prescriber understands the mechanism and clinical rationale. Not just that they checked the boxes.

What If: Wegovy Insurance New Hampshire Scenarios

What If My Initial Wegovy Prior Authorization Gets Denied?

Request the specific denial reason in writing. Insurers must provide it within 72 hours under New Hampshire Insurance Department regulations. Most denials fall into three categories: insufficient BMI documentation (single measurement instead of trend), missing step therapy proof, or incorrect ICD-10 coding for comorbidities. The appeal window is 180 days from the denial date, and the success rate for appeals with corrected documentation exceeds 65% in New Hampshire. Resubmit with explicit documentation addressing the stated deficiency. If the denial cited 'no documented previous weight loss attempt,' include pharmacy records showing phentermine fills or a letter from a dietitian documenting program participation.

What If I'm on Medicare or Medicaid in New Hampshire?

Medicare Part D does not cover Wegovy because federal statute excludes weight loss medications from Part D formularies. This applies to all Medicare Advantage plans in New Hampshire including those from Anthem, Cigna, and Aetna. The only exception is if Wegovy is prescribed for type 2 diabetes management (off-label), in which case some Part D plans cover it as a diabetes medication. But this requires the prescriber to code it as diabetes treatment, not obesity treatment, which creates documentation and liability concerns.

New Hampshire Medicaid (both Standard and Granite Advantage/Medicaid Expansion) added limited Wegovy coverage in July 2025 under specific criteria: BMI ≥35 with documented diabetes or cardiovascular disease, or BMI ≥40 regardless of comorbidity. Prior authorization is required, and approval is limited to 12 months with mandatory weight loss documentation at 3-month intervals. Patients who don't achieve ≥5% weight reduction by month 6 face coverage termination.

What If My Employer's Plan Excludes Weight Loss Medications?

Employer self-funded plans can exclude entire drug classes regardless of FDA approval or medical necessity. Approximately 35% of New Hampshire employer plans exclude anti-obesity medications as of 2026. If your plan summary specifically lists 'weight loss medications' as an excluded category, prior authorization won't overcome the exclusion. Your options: negotiate Wegovy coverage as a diabetes prevention medication if you're prediabetic (A1C 5.7–6.4%), switch to a compounded semaglutide provider not billed through insurance, or appeal to your employer's HR benefits committee citing the AMA's classification of obesity as a disease requiring pharmacological treatment.

The Blunt Truth About Wegovy Insurance Coverage in New Hampshire

Here's the honest answer: most New Hampshire insurance plans that 'cover' Wegovy don't actually make it affordable. Tier 4 and Tier 5 placement means 30–50% coinsurance even after prior authorization approval. That's $400–$700 per month out-of-pocket for most patients. The average New Hampshire deductible for employer-sponsored plans is $2,200 for individuals and $4,500 for families, meaning you'll pay full retail ($1,400+) until your deductible is met.

Manufacturer savings programs. Novo Nordisk's Wegovy Savings Card. Reduce copays to $0–$25 for commercially insured patients, but the card explicitly excludes government insurance (Medicare, Medicaid) and is often rejected by high-deductible health plans. The card works only if your insurance approves the prior authorization first. It doesn't bypass coverage denials.

Compounded semaglutide from 503B facilities costs $250–$350 per month without insurance involvement and doesn't require prior authorization. It's the same active molecule (semaglutide) but lacks FDA approval as a finished drug product. For patients facing repeated PA denials or unaffordable coinsurance, compounded semaglutide is the functional alternative that New Hampshire providers increasingly recommend.

Comparison Table: New Hampshire Insurance Carriers and Wegovy Coverage

Key Takeaways

• Wegovy insurance coverage in New Hampshire requires prior authorization from all major commercial carriers, with approval rates ranging from 55–70% when documentation includes continuous BMI tracking, step therapy proof, and proper ICD-10 comorbidity coding.
• Tier 4 and Tier 5 formulary placement translates to 30–50% coinsurance even after PA approval, meaning most patients pay $400–$700 per month out-of-pocket until they reach annual out-of-pocket maximums.
• Medicare Part D does not cover Wegovy for weight loss under federal statute. Medicare Advantage plans in New Hampshire universally exclude it unless prescribed off-label for type 2 diabetes management.
• New Hampshire Medicaid added limited Wegovy coverage in July 2025 for patients with BMI ≥35 plus comorbidity or BMI ≥40, requiring 3-month weight loss documentation to maintain approval beyond six months.
• Compounded semaglutide from FDA-registered 503B facilities costs $250–$350 per month without insurance involvement and bypasses prior authorization requirements entirely. It's the same active molecule but not the FDA-approved finished drug product.
• Novo Nordisk's Wegovy Savings Card reduces copays to $0–$25 for commercially insured patients but explicitly excludes Medicare, Medicaid, and many high-deductible health plans.

If your insurance denies Wegovy coverage or the approved coinsurance exceeds what you can sustain long-term, compounded semaglutide through a licensed telehealth provider like TrimRx eliminates the prior authorization cycle entirely. The clinical outcome is the same. The administrative burden and cost structure are completely different.